Newsroom | 17061 results
Sorted by: Latest
-
PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine
GOLDEN, Colo.--(BUSINESS WIRE)--Agreement with Immuno Cure adds to PharmaJet's portfolio of global development partnerships with innovative oncology & infectious disease developers....
-
Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization
BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Join Leading Experts from DNAnexus, Olink, & Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration & Standardization...
-
Phase Genomics Launches ProxiMeta™ Starter and Elite Bundles to Expand Access to Genome-Resolved Metagenomics
SEATTLE--(BUSINESS WIRE)--Phase Genomics, Inc., a leader in genomic technology development, today announced the launch of its new ProxiMeta Starter and Elite Bundles, comprehensive product offerings that make genome- and mobilome-resolved metagenomics more accessible for researchers across microbiome, environmental and public health applications. Built on Phase Genomics’ award-winning Hi-C metagenomics platform, the streamlined, full-service solutions accelerate discovery from within complex mi...
-
Clinical Milestones, Vector Innovation Key to Gene Therapy, GenoTher Biocluster’s First International Summit, Atamyo Therapeutics’ Progress for LGMDs Highlight Genethon’s Most Recent Newsletter
PARIS--(BUSINESS WIRE)--Clinical milestones highlighted including those reflected in Genethon’s Phase 3 ready Duchene muscular dystrophy gene therapy (GNT0004)....
-
LabPMM® recibe la aprobación del Estado de Nueva York para el ensayo NPM1 MRD Assay - Ayudará a informar sobre la terapia y a acelerar los ensayos dirigidos
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe se complace en anunciar que su filial de propiedad exclusiva, el Laboratorio de Medicina Molecular Personalizada (Laboratory for Personalized Molecular Medicine®, LabPMM) ha recibido la aprobación del Estado de Nueva York (NYS) para el ensayo denominado NPM1 MRD Assay. Esta aprobación se produce solo dos meses después de obtener la aprobación del Estado de Nueva York para nuestro ensayo FLT3 ITD MRD Assay. Juntas, estas pruebas representan una herramient...
-
LabPMM® recebe aprovação em Nova York para o ensaio NPM1 MRD – Acelerando terapias e ensaios clínicos direcionados
SAN DIEGO--(BUSINESS WIRE)--A Invivoscribe tem o prazer de anunciar que sua subsidiária integral, a Laboratory for Personalized Molecular Medicine® (LabPMM), recebeu a aprovação do estado de Nova York (NYS) para o ensaio NPM1 MRD. Esta conquista ocorre apenas dois meses após a aprovação do NYS para o ensaio FLT3 ITD MRD. Juntos, esses testes representam uma ferramenta essencial para pacientes com leucemia mieloide aguda (LMA), médicos e empresas farmacêuticas, reforçando o compromisso da Invivo...
-
LabPMM® erhält Zulassung des Staates New York für den NPM1 MRD-Assay - Unterstützung der Therapie und Beschleunigung gezielter Studien
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe gibt bekannt, dass seine hundertprozentige Tochtergesellschaft, das Laboratory for Personalized Molecular Medicine® (LabPMM), die Zulassung des Staates New York (NYS) für den NPM1 MRD-Assay erhalten hat. Dies erfolgt nur zwei Monate nach der Zulassung des NYS unseres FLT3 ITD MRD-Assays. Zusammen stellen diese Tests ein wichtiges Instrument für Patienten mit akuter myeloischer Leukämie (AML), für Ärzte sowie für Pharmaunternehmen dar. Die neue Zulassung...
-
Riassunto: LabPMM® riceve l'approvazione dello Stato di New York per il NPM1 MRD Assay - Informare la terapia e accelerare gli studi clinici mirati
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe è lieta di annunciare che la sua controllata, il Laboratory for Personalized Molecular Medicine® (LabPMM) ha ricevuto l'approvazione dallo Stato di New York (NYS) per il NPM1 MRD Assay. Questa approvazione giunge solo due mesi dopo aver ottenuto l'approvazione del NYS per il nostro FLT3 ITD MRD Assay. Insieme, questi test rappresentano uno strumento critico per i pazienti affetti da leucemia mieloide acuta (LMA), clinici e aziende farmaceutiche. La nuova...
-
LabPMM® obtient l’autorisation de l’État de New York pour le test NPM1 MRD visant à informer le traitement et à accélérer les essais ciblés
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe est heureuse d’annoncer que sa filiale à part entière, le Laboratory for Personalized Molecular Medicine® (LabPMM), a obtenu l’autorisation de l’État de New York (NYS) pour le test NPM1 MRD. Cette autorisation intervient deux mois seulement après l’obtention de l’autorisation de l’État de New York pour notre test FLT3 ITD MRD. Ensemble, ces tests constituent un outil essentiel pour les patients atteints de leucémie aiguë myéloïde (LAM), les cliniciens et...
-
Samenvatting: LabPMM® ontvangt goedkeuring van New York State voor de NPM1 MRD Assay - om informatie over therapie te geven en doelgerichte proeven te versnellen
SAN DIEGO--(BUSINESS WIRE)--Invivoscribe kondigt met genoegen aan dat haar dochteronderneming, het Laboratory for Personalized Molecular Medicine® (LabPMM), volledig in handen van het bedrijf, goedkeuring van New York State (NYS) heeft ontvangen voor de NPM1 MRD Assay. Deze goedkeuring komt amper twee maanden nadat NYS-goedkeuring werd verkregen voor onze FLT3 ITD MRD Assay. Samen vertegenwoordigen deze testen een kritiek instrument voor patiënten met acute myeloïde leukemie (AML), artsen en fa...
